TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12181083
Drug: huperzine Alpha
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: huperzine Alpha 400 micro g/day for 12 weeks
Study: 2016620
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human recombinant interferon beta (rIFN‐beta; Betaseron) given by IV infusion over 30 minutes 3 times per week (MWF) with dose escalation: 50-100-200, 100-200-400, 200-300-500, and 300-400-600 x 10(6) IU/m2.
Study: 7326374
Drug: No continuity
Approvals — FDA: no, EMA: no, PMDA: no
Description: No continuity of caregiver or special treatment (Group 4)
Study: 21291943
Drug: Topiramate (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100-200 mg/day)
Study: 18928481
Drug: Nesiritide (NES)
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide (NES) 72-hour infusion at 0.01 mcg/kg/min
Study: 16609069
Drug: Intrathecal triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal triple therapy (MTX, cytarabine, and hydrocortisone sodium succinate)
Study: 8215479
Drug: Granisetron (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3.0 mg/body) with methylprednisolone sodium (750 mg/body)
Study: 8215479
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium (750 mg/body) plus metoclopramide (46.7 mg/body on average) and domperidone (82.9 mg/body on average)
Study: 2485052
Drug: Lisinopril (LIS)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (LIS) 20-80 mg q.d., n = 10
Study: 2485052
Drug: Nifedipine (NIF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NIF) 20-40 mg b.i.d., n = 5
Study: 26842425
Drug: Structured, moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured, moderate intensity physical activity program (n=818) conducted in a center (twice a week) and at home (3‐4 times a week) including aerobic, strength, flexibility, and balance training activities.
Study: 24504686
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.5‐0.8 U/kg)
Study: 24504686
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (SC)
Study: 15730350
Drug: Reserpine 0.5
Normalized name: reserpine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine 0.5 mg
Study: 25218827
Drug: Gabapentin 1800
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1800 mg
Study: 15730350
Drug: Lamotrigine 150
Normalized name: lamotrigine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 150 mg
Study: 10756218
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide 0.25 mg every 6 hours (group A)
Study: 10756218
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide 0.1 mg every 6 hours (group B)
Study: 9161235
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (100 IU in 1 mL saline) administered three times per week for 3 weeks
Study: 9161235
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL saline) administered three times per week for 3 weeks
Study: 8339551
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral simvastatin daily for 2 years
Study: 8339551
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 2 years
Study: 24120718
Drug: i.v. sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. sugammadex 4 mg/kg with oral aspirin 75 mg
Study: 24120718
Drug: i.v. sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. sugammadex 4 mg/kg
Study: 19344563
Drug: Sublingual ketorolac
Normalized name: ketorolac Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ketorolac (30 mg, three doses)
Study: 19344563
Drug: IV metamizole
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV metamizole (1 g)
Study: 9764063
Drug: Electrophysiologically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically guided treatment
Study: 8141445
Drug: Flunitrazepam (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1.2 mg.h‐1) + Fentanyl (1.2 mg.h‐1)
Study: 8141445
Drug: Isoflurane (0.6‐1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane (0.6‐1.2 vol%) + Fentanyl (1.2 mg.h‐1)
Study: 8141445
Drug: Propofol (4‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (4‐8 mg.kg‐1.h‐1) + Fentanyl (1.2 mg.h‐1)
Study: 3290709
Drug: Methylprednisolone and
Normalized name: methylprednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone and Azathioprine combination therapy
Study: 31021890
Drug: Split-dose preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose preparation (4-L polyethylene glycol)
Study: 31021890
Drug: Same-day preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day preparation (4-L polyethylene glycol)
Study: 31021890
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation ≥7 hours before colonoscopy
Study: 28219104
Drug: Captopril (3×50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (3×50 mg/day)
Study: 23142441
Drug: Single-injection femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection femoral nerve block (FNB)
Study: 15910868
Drug: Molsidomine 16
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 16 mg once a day (o.a.d.)
Study: 8574301
Drug: Dehydrating medications
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrating medications
Study: 2503020
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 20 mg sodium cromoglycate
Study: 367509
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg vancomycin six-hourly for five days
Study: 27576774
Drug: Continued thienopyridine
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued thienopyridine therapy (75 to 325 mg aspirin daily)
Study: 28297015
Drug: Continued thienopyridine
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued thienopyridine therapy
Study: 24887576
Drug: Low-dose contrast
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose contrast medium (400 mgI/kg) with 80 kV(p)
Study: 19707728
Drug: 6-h Evidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-h Evidence Based Medicine (EBM) Workshop
Study: 16168039
Drug: Psychotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy and antidepressants
Study: 10456592
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (ear acupuncture)
Study: 1817903
Drug: Unknown anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unknown anesthetic solutions
Study: 6983500
Drug: Trimethoprim (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (300 mg at night)
Study: 6983500
Drug: Co-trimoxazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (two tablets 12-hourly for seven days)
Study: 31442001
Drug: Intraoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative antibiotics prescribed by 95.0% of surgeons
Study: 31442001
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics prescribed by 73.6% of respondents
Study: 31442001
Drug: Factors influencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors influencing intraoperative antibiotic use
Study: 31442001
Drug: Factors influencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors influencing postoperative antibiotic use
Study: 29085957
Drug: Immediate teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate teriparatide therapy
Study: 29085957
Drug: Delayed teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed teriparatide therapy
Study: 25567311
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m² q3w (standard group)
Study: 25567311
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m² q3w (study group)
Study: 25567311
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m² q3w or 100 mg/m² q3w
Study: 22765322
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management augmented with emotionally focused therapy (MM + EFT)
Study: 22765322
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management alone (MM)
Study: 18382805
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (1-3 doses with a one-month interval)
Study: 18382805
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (for patients who failed to respond to placebo)
Study: 11850288
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg telithromycin, once daily for 5 days (Group A)
Study: 11850288
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg telithromycin, once daily for 5 days (Group B)
Study: 11850288
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg telithromycin, once daily for 5 days (Group C)
Study: 11850288
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg telithromycin, once daily for 5 days (Group D)
Study: 12047398
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 microg) administered during insulin clamp studies
Study: 12047398
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without misoprostol) during insulin clamp studies
Study: 9583286
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels (374 +/- 11.9 mg/dL)
Study: 9583286
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels > 300 mg percent
Study: 2768616
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg methylphenidate (Ritalin)
Study: 2768616
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg methylphenidate (Ritalin)
Study: 687500
Drug: Ephedrine 60
Normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 60 or 90 mg
Study: 687500
Drug: Pseudoephedrine 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 210 or 240 mg
Study: 687500
Drug: Ephedrine 60
Normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 60 mg
Study: 687500
Drug: Pseudoephedrine 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 210 mg
Study: 23377843
Drug: Common identity
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common identity treatment (to enhance their sense of commonality)
Study: 19243891
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (0.6 g/kg)
Study: 11349340
Drug: Weekly communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly communication for 6 months via a totally automated, computer‐based voice system.
Study: 8270918
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (antibiotic treatment for asymptomatic UTI)
Study: 2887520
Drug: bopindolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol (1 to 4 mg/day)
Study: 2887520
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 to 200 mg/day)
Study: 29624493
Drug: Pazufloxacin 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin 0.6% BID (twice a day)
Study: 26847148
Drug: LC (Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC (Traditional Chinese Medicine)
Study: 26847148
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard treatment without LC)
Study: 25385295
Drug: hUC‐MSC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hUC‐MSC therapy with anti‐inflammatory treatment
Study: 25385295
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti‐inflammatory treatment only)
Study: 23209076
Drug: C312M vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C312M vaccination via oral, immersion, and oral plus immersion routes
Study: 16206349
Drug: 4 weekly
Normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weekly HMW hyaluronan injections (O4, n = 128)
Study: 16206349
Drug: 3 weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 weekly HMW hyaluronan injections followed by one arthrocentesis (O3A1, n = 120)
Study: 16206349
Drug: 4 arthrocenteses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 arthrocenteses without injection (control group, A4, n = 124)
Study: 16206349
Drug: 4 weekly
Normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weekly HMW hyaluronan injections (O4)
Study: 3317337
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg b.i.d.
Study: 6362699
Drug: Brotizolam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.5 mg
Study: 3531851
Drug: PK10169 low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK10169 low-molecular-weight heparin
Study: 25707875
Drug: Overall graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall graft survival at 5 years with either induction therapy
Study: 17595381
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (CIMT) for 2 weeks
Study: 16815320
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sumatriptan
Study: 23325368
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sumatriptan
Study: 12665269
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (Fluvent) at a daily dose of 22 microg
Study: 12665269
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (Becotide) at a daily dose of 400 microg
Study: 25853591
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and protamine
Study: 7100
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoprolol t.i.d.
Study: 29901379
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg, 1 tablet a day for 4 weeks, then increased to 2 tablets a day for the next 4 weeks)
Study: 29901379
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosing schedule as donepezil)
Study: 20456105
Drug: Pads with
Normalized name: Sani-pads with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pads with different amounts of lotion applied; evaluated for 3 hours using the BTK protocol.
Study: 20456105
Drug: Pads with
Normalized name: Sani-pads with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pads with AGM core; evaluated for lotion transfer.
Study: 20456105
Drug: Pads with
Normalized name: Sani-pads with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pads with cellulose core; evaluated for lotion transfer.
Study: 20456105
Drug: Clinical in-use
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical in-use study on second series of test products; evaluated for lotion transfer.
Study: 18513551
Drug: Capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule endoscopy after an 8-hour fasting period (Group A)
Study: 18513551
Drug: Capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule endoscopy after drinking 2 doses of 45 mL oral sodium phosphate (NaP) (Group B)
Study: 18513551
Drug: Capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule endoscopy (both groups)
Study: 16129742
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate degradable cement (Norian SRS) augmentation
Study: 12860582
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride 1500 mg with chondroitin sulfate 1200 mg
Study: 9264422
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (antiarrhythmic drug therapy)
Study: 7486901
Drug: Clarithromycin (CAM)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CAM) 100 mg, twice a day for 8 weeks
Study: 2344171
Drug: Cefonicid (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (one daily intravenous dose)
Study: 29117996
Drug: Isolated ultrafiltration
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated ultrafiltration (ultrafiltration rate 13.6 ± 3.9 ml·kg⁻¹·h⁻¹)
Study: 18092695
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (percutaneous Kirschner-wiring)
Study: 18092695
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (close reduction and immobilisation in plaster splint)
Study: 15946977
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m(2) on days 1 and 8 and epirubicin 60 mg/m(2) on day 1, 3 weekly for six cycles (VE)
Study: 15946977
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1, 3 weekly for six cycles (AC)
Study: 11828245
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g x d(‐1) during 5 d)
Study: 8733874
Drug: Moderate hypothyroidism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypothyroidism induced by half-dose thyroxine replacement therapy (cutting replacement therapy in half)
Study: 8733874
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (substituting triiodothyronine for thyroxine replacement over a 3-week period, then omitting hormone therapy for 3 weeks)
Study: 1715416
Drug: PEB chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEB chemotherapy (group B)
Study: 29989468
Drug: Multifactorial program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial program (exercise, medication review, and education)
Study: 26789749
Drug: School-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based treatment (SBT) with praziquantel, coverage 84.2%.
Study: 24504198
Drug: Sinusoidal linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinusoidal linear acceleration at 30 mG
Study: 24504198
Drug: Sinusoidal linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinusoidal linear acceleration at 1.25 mG
Study: 24504198
Drug: Sinusoidal linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinusoidal linear acceleration at 10 mG
Study: 24504198
Drug: Sinusoidal linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinusoidal linear acceleration at 6.5 mG
Study: 17327294
Drug: Tobramycin 6
Normalized name: tobramycin 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 6 mg/kg once daily plus penicillin G 5 million IU x 4
Study: 17327294
Drug: Tobramycin 6
Normalized name: tobramycin 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 6 mg/kg three times daily plus penicillin G 5 million IU x 4
Study: 16277774
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with lowest bioavailability
Study: 16277774
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with highest bioavailability
Study: 10467991
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk (1.0 g fat/dl, 3.3 g protein/dl)
Study: 10467991
Drug: Standard-fat milk
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-fat milk (3.5 g fat/dl, 3.3 g protein/dl)